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Extracorporeal photopheresis (ExP) was administered every other week in an outpatient
setting to four patients with chronic refractory psoriasis vulgaris without arthropathy. The
duration of treatment ranged from six to 13 months. Two patients received methotrexate
concomitantly during the initial phase of the study. All patients demonstrated a decrease in
erythema, induration, and scaling oflesional skin, accompanied by incomplete clearing oflesions
such that the percentage of involvement (SI) ranged between 40 to 80 percent ofbaseline scores.
Exacerbations of psoriasis occurred with minor provocations, and two patients who were
predisposed to developing epithelial skin neoplasms as a consequence of prior treatments
continued to develop tumors during the study interval. Prolonged ExP treatment was otherwise
well tolerated, without evidence of toxicity on routine laboratory safety tests or changes in
lymphocyte counts. All patients, however, exhibited decreased intradermal skin responses to
recall antigens and a decreased capacity of peripheral lymphocytes to produce interleukin 2
(IL-2) in response to polyclonal stimuli in vitro. These observations suggest that the observed
anti-inflammatory effect of alternate-week ExP on psoriasis is mediated in part to a direct
inhibition oflymphokine production or release by psoralen-ultraviolet-exposed lymphocytes.
INTRODUCTION
Extracorporeal photochemotherapy or photopheresis (ExP) is a recently introduced
treatment for patients with cutaneous T-cell lymphoma (CTCL) and potentially other
lymphocyte-mediated disorders [I]. With this procedure, peripheral blood leukocytes
(containing about 50 percent lymphocytes) are collected by discontinuous leukaphere-
sis, combined with plasma containing the photoactive drug 8-methoxypsoralen (8-
MOP) which the patient takes as an oral dose about two hours before, and then
exposed to long-wave ultraviolet radiation (UVA) before reinfusing the lethally
irradiated cells back to the patient. Edelson has postulated that the reinfused
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photomodified malignant cells present in the peripheral blood may provide a potent
immunogenic stimulus that leads to the development ofclonotypic inhibitory immune
responses against the malignant T cells in CTCL [2,3].
Considering the mounting evidence that lymphocyte-mediated responses play an
important role in the pathogenesis ofpsoriasis [4-7], weconducted a pilot study in four
patients with severe psoriasis vulgaris to determine whether ExP might be therapeuti-
cally useful in this disease [8]. This report presents preliminary evidence that
administration of ExP every other week has anti-inflammatory effects in psoriasis
because of direct effects on circulating lymphocytes reminiscent of those produced by
cyclosporine A [6,9].
METHODS
Patients
Four patients with severe refractory psoriasis vulgaris were treated with ExP
between July 1987 and October 1988 in an outpatient facility located at Skin and
Cancer Hospital, Temple University Health Sciences Center. All had long-standing
psoriasis vulgaris, with plaques involving more than 30 percent ofthe body surface and
historical evidence offailing to respond adequately to standard antipsoriatic treatment
regimens, and none had evidence of psoriatic arthropathy. Patients 2 and 4 had
previously been treated with large cumulative doses ofpsoralen-ultraviolet A (PUVA),
resulting in the formation of multiple epithelial neoplasms in the years preceding the
start of ExP. Patient 2 had had five actinic keratoses, 14 keratoacanthomas, one basal
cell carcinoma, and four squamous cell carcinomas removed since 1980; patient 4 had
had three keratoacanthomas and one basal cell carcinoma removed since 1985. Patient
4 had also experienced methyldopa-induced arthralgias and myalgias associated with a
positive 1:1,280 antinuclear antibody (ANA) titer in 1977. Her ANA remained
weakly positive off the drug and was 1:40 at the start of ExP. The clinical data
concerning the four treated patients is summarized in Table 1.
Treatment Protocol
Each ExP session consisted of the oral administration of methoxypsalen (8-MOP,
Oxsoralen, Elder, Bryan, OH) at a dose of 0.6 mg/kg, followed two hours later by
collection of leukocyte-enriched blood by discontinuous leukapheresis, using the
prototype of the UVAR Photopheresis System (Therakos, King of Prussia, PA). A
total of 240 ml of leukocyte-enriched blood is collected and combined with 300 ml of
the patient's plasma and 200 ml of sterile normal saline, and then passed as a 1 mm
film through a six-chambered disposable sterile cassette exposed to long-wave ultravio-
let (UVA) radiation in order to activate the 8-MOP. The leukocyte mixture is given a
270-minute exposure, which provides the average cell with 2 J/cm2 of UVA radiation.
After the irradiation phase, the entire amount ofblood is returned to the patient. Each
patient also underwent an initial mock treatment session in which 8-MOP was taken
and blood was collected and reinfused without exposure to UVA. Thus, ExP provides
for the exposure of a large number of peripheral blood lymphocytes to the effects of
photoactivated 8-MOP.
Response to treatment was assessed using two scoring parameters: the percentage of
skin surface involvement (SI) and the psoriasis area and severity index (PASI)
described originally by Fredriksson and Pettersson [10]. The maximum possible scores
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TABLE 1
Clinical Information on Patients with Psoriasis Vulgaris Treated with Extracorporeal Photopheresis
Duration of
Age, Race, Disease Other Skin
Patient Sex (years) Prior Treatments Problems
1 46, W, M 12 Tar + UVB Lichen simplexchronicus
PUVA (112 J/cm2) Tinea pedis/cruris
MTX (625 mg)
2 49, W, M 21 Prednisone Epithelial tumorsa
Isotretinoin Herpes zoster
MTX (2,365 mg) Verrucae
PUVA (> 4,100 J/cm2)
3 27, W, F 10 Prednisone None
Tar + UVB
PUVA
4 50, W, F 31 Tar + UVB Epithelial tumorsa
MTX (595 mg) Herpes zoster
PUVA (> 8,000 J/cm2)
aRefer to text for details about tumor types.
for SI and PASI were 100 percent and 72.0, respectively. Punch biopsy specimens from
representative psoriatic plaques were taken at three-month intervals and processed for
histopathology and immunohistochemistry, using methods previously reported [11].
Intradermal skin testing to Candida (1:500), trichophytin (1:500), and PPD-tubercu-
lin (5TU) antigens was performed at six-month intervals.
All patients were monitored at regular intervals throughout the study for evidence of
toxicity with a battery of tests, including complete blood counts, biochemical profile,
urinalysis, electrocardiograms, and chest roentgenograms. Additional blood samples
were obtained at three-month intervals for levels of serum immunoglobulins (IgG,
IgM, IgA, and IgE), the C3 and C4 components of complement, ANA and anticyto-
plasmic antibodies (anti-Ro, anti-La), circulating immune complexes, and blood
lymphocyte subset analysis, using a panel of commercially available murine mono-
clonal antibodies (Table 2).
Patients also had blood samples taken one week after the mock treatment session
(baseline) and one week after the first (week 1), seventh (three-month), and thirteenth
(six-month) ExP sessions for measurement of interleukin 2 (IL-2) responses by
lymphocytes in vitro to concanavalin A and staphylococcus enterotoxin B. Peripheral
blood mononuclear cells were cultured at 106 cells/ml in a tissue culture medium
composed of RPMI-1640, supplemented with 5 percent AB serum and 2 mg/ml
glutamine for 48 hours at 370C with or without mitogen stimulation. The supernatants
were collected at the termination ofculture, and the IL-2 produced was determined by
a method modified from Gillis et al. [12]. This assay is based on the capacity of
IL-2-containing supernatants to support the growth of the IL-2-dependent cell line
CT-20. CT-20 cells were washed three times and resuspended in Dulbecco's minimal
essential medium, supplemented with 2 percent fetal calf serum and 50 mcg/ml
gentamicin, and 104 cells were placed in 96-well microplates containing serial dilutions
of the supernatants to be tested. After incubation for 20 hours, 0.5 ACi tritiated
thymidine was added, and the thymidine uptake was measured after an additional four
hours. Calculation of unit values was carried out as described by Gillis [12].
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TABLE 2
Monoclonal Antibodies Used to Immunophenotype Peripheral Blood Lymphocytesa
Cluster Antigen
Antibody Source Designation Distribution
T-cell Markers
OKT11 Ortho CD2 Pan T-cell, NK cells (SRBC receptor)
OKT3 Ortho CD3 Pan T-cell (TCR complex)
OKT4 Ortho CD4 T helper/inducer, monocytes
OKT8 Ortho CD8 T suppressor/cytotoxic, NK subset
B-cell Markers
Leul2 B-D CD19 Pan B-cell
Leu16 B-D CD20 Pan B-cell, dendritic cells
Anti-kappa Tago Pan B-cell
Anti-lambda Tago Pan B-cell
Activation Markers
Anti-HLA-DR B-D DR Class II MHC antigen
Anti-Tac Otherb CD25 Activated T-cells (IL-2 receptor)
5E9 ATCC CD71 Transferrin receptor
OKTIO Ortho CD38 Restricted multiple lineages
Other Markers
Leu7 B-D CD57 NK cells
Leul 1 B-D CD16 NK Cells, PMNs
LeuM3 B-D CD14 Monocytes, PMNs
OKT6 Ortho CDla Thymocytes, Langerhans cells
°B-D, Becton-Dickinson, Mountain View, CA; Ortho, Ortho Diagnostic Systems, Raritan, NJ; ATCC,
American Type Culture Collection, Rockville, MD; NKcells, natural killer cells; PMNs, Polymorphonu-
clear cells; MHC, mixed histocompatability complex
bAnti-Tac antibody is a gift from Thomas Waldmann, M.D.
RESULTS
Clinical Observations
All patients improved to some degree while on ExP (refer to [8] for details). The
responses were characterized by decreasing erythema, induration, and scaling initially,
followed by actual clearing ofsome, but not all lesions (Table 3). Of the two response
parameters, PASI was much more sensitive to the changes in inflammatory events in
lesional skin, correlated well to the patient's symptomatology, and often preceded
changes in SI by several weeks; however, SI provided the more clinically relevant
parameter tojudge overall response.
Compliance to the protocol by all patients was excellent. Patients I and 2 were
treated concomitantly with methotrexate (MTX) given orally at a dose of 25 mg every
other week, alternating with ExP to prevent an exacerbation of disease. Gradually,
over the next six months, the dose of MTX was decreased and eventually discontinued.
Both patients steadily improved on combined therapy to reach an optimum PASI and
SI scores of 2.7 and 9 percent for patient I and 5.4 and 30 percent for patient 2,
respectively. When maintained on ExP alone, however, their psoriasis began to flare
such that lower, previously ineffective doses of MTX (12.5 mg every other week) were
administered to determine whether combination therapy would be of benefit. Patient I
responded only minimally to this regimen, but patient 2 again showed steady
improvement until the end ofthe study.
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TABLE 3
Summary of Response Scores in Patients with Psoriasis Vulgaris Treated with ExP
Patient ExP Session Week PASI SI (%) Histopathology
1 Mock 0 18.0 40 Acute
7 13 14.4 37 Acute
13 25 2.7 10 Chronic
19 37 13.5 17 Subacute
25 (end) 49 15.3 20 Subacute
2 Mock 0 26.7 49 Chronic
7 13 5.4 30 Subacute
13 25 9.4 38 Acute
19 37 18.8 67 Subacute
25 49 6.5 43 Acute
29 (end) 57 7.1 41 ND
3 Mock 0 15.9 48 Acute
7 13 5.2 26 Chronic
13 (end) 25 8.5 24 Subacute
4 Mock 0 14.9 48 Acute
7 13 24.3 51 Acute
13 25 6.0 38 Chronic
19 37 4.8 24 ND
23 (end) 45 30.4 72 ND
ND, not done
The other two patients were treated with ExP alone. The psoriasis of patient 3
responded partially over the first three months (PASI, 5.2; SI, 24 percent) but then
became worse due to seasonal factors, and she elected to discontinue ExP after six
months. The psoriasis of patient 4, after an initial mild exacerbation attributed to
withdrawal from prior treatments, improved steadily over the next seven months to a
PASI of4.6 and SI of 23 percent. With the change in the season, however, her disease
flared severely beginning after the nineteenth treatment session (37 weeks), and she
had to be hospitalized.
ExP was extremely well tolerated and not accompanied by evidence of toxicity on
laboratory safety tests. During the study interval, however, patient 2 developed ten
keratoacanthomas and one squamous cell carcinoma, and patient 4 developed one
keratoacanthoma and two squamous cell carcinomas. These lesions occurred primarily
on the legs, which had received extra treatments ofPUVA in the past.
Post-Treatment Observations
A few clinical observations have been made in the 12 months after ExP that may
pertain to chronic or delayed effects ofExP. Patient 1, who had chronic tinea pedis and
cruris due to Trichophyton rubrum, developed Majocchi's granuloma on the left arm
ten months after ExP (Fig. 1). There otherwise was nothing unusual about his
dermatophyte infection. Patient 2, who had long-standing verrucae on the legs prior to
ExP, observed most ofthese lesions to regress spontaneously 28 weeks after ExP (Fig.
2). Skin testing to recall antigens remained unreactive, but the production of IL-2 by
peripheral lymphocytes was found to be increased (see below). The persistent low-titer
ANA level of patient 4 prior to ExP (baseline measurement, 1:40) became unreactive
after six months of ExP, but was again positive (1:320) when checked six months after
completing ExP.
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FIG. 1. Cluster of infiltrated papules
that developed on the forearm of
patient I ten months after stopping
ExP. A biopsy specimen showed fea-
tures of a suppurative and granuloma-
tous folliculitis with hyphae within a
changes iteA .F ptn2hair shaft in the dermis consistent with
Majocchi's granuloma.
Pathology
There generally was good agreement between histopathologic findings and the
overall clinical status of the patient (Table 3). The baseline biopsy specimens from
three patients (patient 1, patient 3, and patient 4) showed the features of acute
psoriasis prior to ExP and less acute changes in subsequent analyses corresponding to
changes in the PASI. For patient 2, however, the histopathologic features correlated
poorly with the PASI, possibly the result ofsampling "hot spots" within an improving
psoriatic lesion [13]. The immunopathologic findings on the same specimens corre-
lated less well to the clinical status. All patients exhibited a clear predominance of
CD4+ cells in the dermal infiltrate of baseline biopsy specimens, resulting in a high
CD4/CD8 ratio, as might be expected in actively evolving psoriasis. In patients 2 and
4, the specimens at nine months contained an increased number of CD8± cells, as
might be expected in regressing lesions. The level of Tac expression by lymphoid cells
varied from nearly absent to low levels and did not correlate with improvement or
exacerbations of disease. In the epidermis, the number ofkeratinocytes expressing T9
and DR antigen varied considerably without apparent correlation to disease activity.
Many dendritic cells (Langerhans cells) were also DR-positive. ~~~~~~j
FIG. 2. A. Multiple verrucae on the feet of patient 2 prior to the start of ExP. B. Regression of
verrucae to leave hyperpigmentation seven months after stopping ExP.
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TABLE 4
Skin Test Results in Patients Treated with Extracorporeal Photopheresisa
Patient Antigen Pre-ExP 6 Months 12 Months Post-ExPb
1 PPD neg neg neg pos (Io mm)
Trichophytin pos (30 mm) neg neg neg
Candida neg neg neg neg
2 PPD ?pos (5 mm) neg neg neg
Trichophytin pos (15 mm) neg neg neg
Candida neg neg neg neg
3 PPD neg neg ND ND
Trichophytin neg neg ND ND
Candida neg neg ND ND
4 PPD neg neg neg neg
Trichophytin pos (11 mm) neg neg neg
Candida neg neg neg neg
aSkin test results recorded as neg (negative), pos (positive) with millimeters of induration at 48 hours, or
ND (not done)
bSkin testsapplied at 16,20/30, and 22 weeks afterdiscontinuing ExP onpatients 1, 2, and4,respectively
Skin Testing
The results of intradermal skin testing to Candida, trichophytin, and PPD-
tuberculin antigens are presented in Table 4. Three patients reacted positively to at
least one recall antigen prior to starting ExP, and all became non-reactive within the
first six months oftreatment. Moreover, the tests remained negative for at least several
months after treatments had been stopped.
Lymphocyte Subsets and Immunoglobulins
Changes observed on absolute lymphocyte counts, lymphocyte subsets, and serum
IgE levels are summarized in Table 5. The absolute lymphocyte counts for all patients
were within normal limits throughout the study except for patient 3, whose baseline
lymphocyte count was increased (WBC, 7,500, with 57 percent lymphocytes); this
count promptly reverted to normal on subsequent tests. Quantitative IgG, IgM, and
IgA levels remained within normal limits. None of the patients developed evidence of
antinuclear or anticytoplasmic antibodies, immune complexes, or altered complement
levels.
Immunophenotyping revealed only minor changes in lymphocyte subsets for each
patient (Table 5). Patient I showed an absolute decrease in B cells, which remained
unchanged during the study, and only a transient decrease in the number of CD8+
cells at three months. Patient 2 had a normal absolute number ofT cells in the baseline
specimen, but below normal numbers in specimens obtained at three, six, and 12
months, although the CD4/CD8 ratio remained relatively constant. In addition, there
was a relative increase in natural killer (NK) cells and decrease in B cells in the
baseline specimen, followed by gradual normalization of these parameters during
treatment. Patient 3 had an absolute increase in both CD4 and CD8 cells in the
baseline sample, particularly the CD8+ subset, and this increase resulted in a low
CD4/CD8 ratio. The high baseline absolute T-cell count of patient 3 decreased to
normal within three months, with CD4+ cells affected slightly more than CD8 + cells,
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TABLE 5
Selected Blood Immunologic Parameters in Patients Treated with Extracorporeal Photopheresis
Patient Parameter Pre-ExP 3-Month 6-Month 9-Month 12-Month
1 PASI 18.0 14.4 2.7 13.5 15.3
Lymphocyte count 1,575 2,418 1,966 1,650 1,462
% T cells 78 60 71 68 79
CD4/CD8 ratio 2.8 5.0 2.6 2.0 3.5
%Bcells 3 2 6 3 4
%NKcells 9 8 4 11 ND
Serum IgE (IU/ml) 432 598 340 ND 593
2 PASI 26.6 5.4 9.4 18.8 6.5
Lymphocyte count 2,480 1,670 1,524 2,050 1,670
% T cells 58 52 57 64 50
CD4/CD8 ratio 1.3 1.7 1.5 1.9 1.7
%Bcells 3 8 10 12 6
% NK cells 19 18 9 8 ND
IgE 476 518 383 ND 486
3 PASI 15.9 5.2 8.5 ND ND
Lymphocyte count 4,275 1,647 1,848 ND ND
% T cells 85 69 62 ND ND
CD4/CD8 ratio 1.1 1.4 0.7 ND ND
% B cells 10 17 14 ND ND
% NK cells ND ND 12 ND ND
IgE 385 254 168 ND ND
4 PASI 14.9 24.3 6.0 9.2 ND
Lymphocyte count 1,311 1,496 1,380 1,418 ND
% T cells 57 62 67 54 ND
CD4/CD8 ratio 3.7 4.4 5.3 3.9 ND
% B cells 38 32 25 34 ND
% NK cells <1 5 <1 2 ND
IgE 222 266 289 ND ND
ND, not done
resulting in a further decrease in the CD4/CD8 ratio. Patient 4 showed a low to
low-normal absolute T-cell count, mostly due to a decrease in CD8+ cells, resulting in
an increased CD4/CD8 ratio. Furthermore, the NK cell population was decreased
throughout the study and this effect contributed to the relative, but not absolute
increase in B cells.
Activation/proliferation antigens on blood lymphocytes were not found to be a very
useful parameter to monitor disease activity or response to treatment. It is worth
noting, however, that the level of Tac+ cells in the blood was often increased slightly
compared to that of normal blood in these patients (data not shown).
Serum IgE levels were increased slightly in all four patients and remained
unchanged during treatment, except for patient 3 whose IgE level normalized.
Interleukin 2 Measurements
The production of IL-2 by peripheral blood lymphocytes in response to concanavalin
A and staphylococcus enterotoxin B in vitro decreased promptly after starting ExP in
all patients and was below detection by six months in three patients (Table 6). In
patient 2, the study was repeated 29 weeks after ExP ended and was found to have
recovered to above baseline levels.
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TABLE 6
Production of Interleukin 2 (IL-2) by Peripheral Blood Lymphocytes in Response to Polyclonal Stimulia
Patient Timeb 1 mcg Con A 10 mcg Con A 10 mcg SEB
1 Post-mock 0.33 ± 0.02c 1.66 ± 0.09 1.60 ± 0.10
Week 1 0.32 ± 0.03 0.45 ± 0.07 1.23 ± 0.15
Week 7 0.14 ± 0.02 0.21 ± 0.03 ND
Week 13 <0.09 <0.09 <0.09
2 Post-mock 0.24 ± 0.02 0.73 ± 0.05 ND
Week 1 0.09 ± 0.01 0.31 ± 0.04 0.14 ± 0.10
Week 7 <0.09 <0.09 <0.09
Week 13 <0.09 <0.09 <0.09
Post-ExP 1.90 ± 0.20 2.40 ± 0.19 2.60 ± 0.22
3 Post-mock 0.21 ± 0.02 0.38 ± 0.04 0.64 ± 0.06
Week 1 <0.09 0.12 ± 0.01 0.26 ± 0.03
Week 7 <0.09 <0.09 <0.09
4 Post-mock 0.70 ± 0.14 1.10 ± 0.08 1.30 ± 0.13
Week 13 <0.09 0.41 ± 0.04 0.62 ± 0.06
Three normal controls 0.29 ± 0.05 0.82 ± 0.06 1.50 ± 0.15
aCon A, concanavalin A; SEB, staphylococcal enterotoxin B; ND, not determined
bSpecimens were taken 1 week after Mock treatment, and 1 week after the first, seventh, and thirteenth
ExP treatments; patient 2 had an additional specimen taken 29 weeks afterstopping ExP.
"Values expressed as mean ± standard deviation in units relative to an IL-2 standard
DISCUSSION
Recent studies indicate that cellular immune mechanisms play an important role in
the pathogenesis of psoriasis [4-6]. The linkage to certain HLA haplotypes suggests
that the inflammatory and immunologic events in psoriasis are under immunogenetic
control. Lymphocytes are the earliest cells found in incipient psoriatic lesions [14], and
T cells predominate in the dermal infiltrate of established lesions [15-19], together
with dendritic antigen-presenting cells [17,20]. The in situ ratios of T-helper to
T-suppressor cells in the dermal infiltrate is relatively increased in developing psoriatic
lesions and relatively decreased in regressing lesions [21]. The majority ofthese T cells
are activated and express class II MHC molecules (HLA-DR) and the IL-2 receptor
[8,17,21-23]. Expression of HLA-DR by keratinocytes, a common finding in many
inflammatory diseases [24], is thought to be the result of interferon gamma (IFN-
gamma) produced by the activated T cells [25,26]. Stimulated keratinocytes also
elaborate interleukin I (IL-1) and other immunoregulatory cytokines, which could
enhance the inflammatory changes of psoriasis [27-29]. For example, when injected
into human skin, IL-1 alpha causes erythema and edema, with marked mononuclear
cell infiltrate [30]. IL-1 also may contribute to the epidermal proliferation [31] and
neutrophil chemotaxis [32,33] that are characteristic of psoriasis. Likewise, systemic
IL-2 administration has been reported to exacerbate psoriasis [34].
Our immunopathologic studies are consistent with previous reports showing CD4+
lymphocytes to predominate in the dermal infiltrate of active psoriasis, with an
increased number of CD8+ cells in lesions undergoing resolution in two patients who
were studied by us. Discrepant results may possibly have resulted from histologic
heterogeneity within psoriatic plaques [13]. Tac levels were relatively low compared
with malignant and premalignant T-cell lymphoproliferative disorders such as cuta-
neous T-cell lymphoma [35] or lymphomatoid papulosis [36], and correlated with
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disease activity only in patient 2. Expression of class II MHC antigens (DR) by
keratinocytes was found in both acute and chronic psoriatic lesions and did not
correlate well with the overall clinical status of the patient. The expression of high
levels of T9 (transferrin receptor) by keratinocytes, especially in the basal layer, is a
new, but not unexpected finding, since T9 expression is generally increased in
proliferating cells. The prognostic significance ofthis finding or its value in monitoring
response to therapy will have to bedetermined. Patient 4 showed a marked reduction in
T9 expression at the time ofbest response.
Although conducted on a small number of patients, this study provides preliminary
evidence that ExP given on an alternate-week schedule has a definite, but incomplete
therapeutic benefit for patients with severe psoriasis vulgaris refractory to standard
therapies, that the response can be enhanced by the concurrent administration of low
doses of MTX, and that treatment is well tolerated by patients. The mechanism
underlying the response of psoriasis to ExP is unknown but presumably is related in
part to a direct effect on lymphocyte function. In this regard, the finding that
peripheral blood lymphocytes obtained from patients undergoing treatment lose the
capacity to produce IL-2 in vitro may be relevant, since it is reminiscent ofthe cellular
effects of cyclosporine A, which has been used to treat severe psoriasis [9,37,38]. A
major advantageof ExPcompared tosystemicdrugs is that the bone marrow and other
organs are spared the direct toxic effects oftreatment.
The effect on IL-2 production in vitro, the decreased reactivity to skin test recall
antigens, and the possible accelerated formation of epithelial skin neoplasms in
predisposed patients suggests that ExP may be immunosuppressive. Since, however,
blood samples for the IL-2 assay were obtained one week after treatments with ExP, it
may be that the observed inhibition of IL-2 is only a transitory phenomenon limited to
the immediate post-treatment period. Measurements at other time points are needed to
clarify the significance of this observation. Likewise, it is possible that positive skin
tests may have become unreactive during ExP because of the generation of specific
inhibitory responses against T cells mediating the skin test responses, analogous to the
mechanism proposed for autoimmune diseases [2]. Finally, the acceleration in
formation ofepithelial skin tumors may be more apparent than real, since both patients
had a history of developing such tumors predating the onset of ExP, and one patient
was treated concomitantly with MTX. Nevertheless, we feel this observation is
sufficiently provocative to warrant reporting it. Prolonged ExP did not result in a
reduction ofabsolute lymphocyte counts or major alterations in lymphocyte subsets in
the peripheral blood.
The clinical experience with ExP in erythrodermic variants of CTCL is relevant to
provide perspective to the current results. As recently summarized by Edelson [3],
patients with this condition usually receive two consecutive sessions of ExP at
four-week intervals. The best responses occurred in patients who were immunocompe-
tent, suggesting that they might be able to mount an immunologic response to
photomodified malignant T cells. Immunodeficient patients also may respond signifi-
cantly to ExP if treatments are given more frequently, which is probably the
consequence ofthesimple physical destruction oftumor cells. Ourobservations suggest
that an additional biologic mechanism, namely inhibition oflymphokine production or
release by psoralen-ultraviolet-exposed cells, may contribute to the clinical benefit in
CTCL, particularly for those with erythrodermic manifestations. Indeed, one ofus has
observed a patient with Sezary syndrome whose erythroderma cleared completely on
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ExP, despite retaining the presence of a chromosomally abnormal malignant T-cell
clone in the blood [Vonderheid E: personal observation].
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